Allergic asthma is a chronic inflammatory remitting-relapsing disease affecting the airways. Long-lived allergen-specific memory CD4 T helper 2 (Th2) cells in mice persist in lungs for more than 2 years after the induction of experimental allergic asthma (EAA). To further understand lung Th2 memory cells, we tracked CD4 T cells in spleen and lungs from healthy mice, through the initiation of acute EAA, recovery (remission), and allergen-induced disease relapse. We identified a lung CD3CD4 cell subset that expresses CD44CD62LCD69ST2, produces Th2 cytokines, and mediates allergen-induced disease relapse despite treatment with FTY720 and anti-CD4 antibody. These cells reside in the lung tissue for the lifetime of mice (>665 days) and represent long-lived pathogenic Th2 tissue resident memory cells (T) that maintain "allergic memory" in lung. We speculate that these data implicate that human Th2-T sentinels in lungs of patients are poised to rapidly respond to inhaled allergen and induce asthma attacks and that therapeutic approaches targeting these cells may provide relief to patients with allergic asthma.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6493194 | PMC |
http://dx.doi.org/10.3389/fimmu.2019.00840 | DOI Listing |
Allergy Asthma Clin Immunol
January 2025
Department of Pediatrics, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama, Japan.
Background: The incidence of allergic diseases has been increasing in Japan. In particular, a serious decline in the age of onset of allergic rhinitis has been observed. Passive smoking from parental smoking has a significant impact on children's health; however, it is difficult to restrict smoking in the home.
View Article and Find Full Text PDFNPJ Prim Care Respir Med
January 2025
Erasmus MC, Department of General Practice, Rotterdam, The Netherlands.
Asthma and allergic rhinitis (AR) are common disorders of the respiratory tract that often coincide. Control of AR symptoms can improve asthma outcomes in patients with co-existing diseases. Our aim is to produce a systematic review of the effectiveness of conventional anti-AR medication for asthma outcomes in patients with both diseases.
View Article and Find Full Text PDFAnn Allergy Asthma Immunol
January 2025
The First Clinical Medical College of Guangzhou University of Chinese Medicine, Guangzhou, 510405, China; The First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, 510405, China; Lingnan Institute of Otolaryngology, Guangdong Clinical Research Academy of Chinese Medicine, Guangzhou, 510405, China. Electronic address:
Background: Allergic rhinitis (AR) is a prevalent chronic inflammatory condition that significantly impacts patient quality of life and poses a substantial public health burden. Recent advancements in metabolomics have facilitated a deeper understanding of the metabolic pathways involved in AR, offering potential for new biomarkers and therapeutic targets.
Objective: This article aims to conduct a systematic review and meta-analysis of clinical studies summarizing the metabolomic profiles of allergic rhinitis (AR) to gain deeper insights into the metabolic changes and pathological processes underlying AR.
Int Immunopharmacol
January 2025
Laboratório de Citocinas Dept. of Immunology Instituto de Microbiologia Prof. Paulo de Góes Universidade Federal do Rio de Janeiro Rio de Janeiro Brazil.
Introduction: The spectrum of eosinophil functions has expanded from fighting helminths to multiple novel roles in malignancy, infection, cancer, and metabolism. In asthma, glucocorticoids, prostaglandins (PG), and cysteinyl-leukotrienes (LT) regulate eosinophil biology through separate signaling pathways. Here we've evaluated the complex interplay between Dexa, PGE2, and CysLTs in eosinopoiesis and eosinophil biology in an allergic asthma model.
View Article and Find Full Text PDFBiomed Pharmacother
January 2025
College of Veterinary Medicine and BK21 FOUR Program, Chonnam National University, 77 Yong-bong-ro, Buk-gu, Gwangju 61186, Republic of Korea. Electronic address:
Silibinin, a major compound of silymarin, has been reported to alleviate respiratory diseases including acute lung injury, asthma, chronic obstructive pulmonary disease, and pulmonary fibrosis through its antifibrotic, anti-inflammatory, and antioxidant properties. However, the specific mechanisms underlying its therapeutic effects, particularly in allergic asthma, are not fully understood. With the increasing prevalence and impact of allergic asthma, there is a need to elucidate the exact underlying mechanisms of its potential treatment effects.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!